Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.43 USD
Change Today +0.0066 / 1.56%
Volume 4.5K
RGRX On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

regenerx biopharmaceuticals (RGRX) Snapshot

Open
$0.43
Previous Close
$0.42
Day High
$0.43
Day Low
$0.42
52 Week High
05/4/15 - $0.60
52 Week Low
09/2/14 - $0.11
Market Cap
43.7M
Average Volume 10 Days
48.7K
EPS TTM
$-0.05
Shares Outstanding
101.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for REGENERX BIOPHARMACEUTICALS (RGRX)

Related News

No related news articles were found.

regenerx biopharmaceuticals (RGRX) Related Businessweek News

No Related Businessweek News Found

regenerx biopharmaceuticals (RGRX) Details

RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of molecules for tissue and organ repair. The company develops and markets its product candidates based on Thymosin beta 4 (Tß4), an amino acid peptide. It develops RGN-259, a topical eye drops that that has completed the Phase IIa exploratory clinical trials and for the regeneration of corneal tissues damaged by injury, disease, or other pathology; and RGN-352, an injectable formulation, which has completed Phase I clinical trials and is intended to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications treated by systemic administration. The company also develops RGN-137, a topical gel that is in Phase II clinical trials and intended for the treatment of epidermolysis bullosa, pressure ulcers, and venous stasis ulcers. In addition, it seeks to identify and evaluate Tß4 peptide fragments and derivatives for use as components in cosmeceutical and consumer products. The company has a strategic partnership with Defiante Farmaceutica S.A. for the development and marketing of RGN-137 and RGN-352 for specified indications in Europe and other countries. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in 2000. RegeneRx Biopharmaceuticals, Inc. was founded in 1982 and is headquartered in Rockville, Maryland.

2 Employees
Last Reported Date: 03/31/15
Founded in 1982

regenerx biopharmaceuticals (RGRX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $110.8K
Compensation as of Fiscal Year 2014.

regenerx biopharmaceuticals (RGRX) Key Developments

Regenerx Biopharmaceuticals Inc. Announces New Publication Elaborates on TB4's Effects on Dry Eye Syndrome and Other Potential Ophthalmic Disorders

RegeneRx Biopharmaceuticals Inc. announced a new peer-reviewed publication describing Thymosin beta 4's (TB4) effects on dry eye syndrome and its potential value for the treatment of other ophthalmic disorders. The authors of the paper explained how TB4's reported mechanisms of action help alleviate the signs and symptoms of dry eye by promoting stem cell recruitment and cell migration, reducing inflammation and apoptosis, enhancing cytoprotection, and promoting gene expression. These multiple activities are responsible for a potential paradigm shift in the treatment of dry eye disorders. Current treatments aim to keep the eye moist and let the natural repair process function, which can take months, if at all. RGN-259, TB4 formulated as a sterile, preservative-free eye drop, is designed to protect and repair the injured dry eye and improve the rate and degree of healing. It is currently in late clinical trials. The authors also addressed additional ocular disorders that may be improved with TB4 treatment. These are based on the defined mechanisms of action of the molecule in the eye and include blepharitis, graft vs. host disease, limbal stem cell deficiency, and following eye surgery such as post-refractive surgery.

RegeneRx Biopharmaceuticals, Inc. Provides Update on Clinical Trials in U.S., Korea and China

RegeneRx Biopharmaceuticals Inc. provided an update on the status and timing of the four ophthalmic clinical trials for dry eye syndrome and neurotrophic keratopathy (NK) scheduled to commence in the U.S., Korea, and China this year. In Korea and China the dry eye trials are being sponsored by RegeneRx's strategic partners in their respective territories. In the U.S., the dry eye and NK clinical trials are being sponsored by ReGenTree, LLC, a joint venture between RegeneRx and G-treeBNT. RGN-259/GBT-201 is a sterile, preservative-free ophthalmic eye drop that is being tested in the trials. Representatives of G-treeBNT and RegeneRx recently met with the U.S. Food and Drug Administration to finalize details of the Phase IIb/III trial in patients with dry eye syndrome, which is being sponsored by ReGenTree, LLC. Based on the positive outcome of the meeting, ReGenTree is preparing to enroll patients in the U.S. dry eye and NK clinical trials in September 2015. The Phase IIb/III dry eye trial is expected to be completed during the first half of 2016 and the Phase III NK trial is expected to be completed in the second half of 2016, or sooner, depending on the speed of patient accrual for this orphan indication. Additionally, ReGenTree has successfully completed the manufacturing required for Phase III and RGN-259 will soon be shipped to the contract research organization (CRO) managing the clinical trials in the U.S.

Regenerx Biopharmaceuticals Inc. Announces Peer-Reviewed Publication of the Results of Recent Cardiac Stem Cell Clinical Trial

Regenerx Biopharmaceuticals Inc. announced a peer-reviewed publication of the results of a recent cardiac stem cell clinical trial that demonstrates the potentially key role that Thymosin beta 4 (TB4) plays in the functional repair of cardiovascular disease. The REGENERATIVE-IHD trial is the largest, randomized, placebo-controlled clinical trial in the UK, to date, which was designed to investigate the use of autologous bone marrow-derived stem cells to improve cardiac function and symptoms in heart failure patients. As part of the trial, the authors studied a cohort of patients to determine if TB4 levels were affected by injection of stem cells and whether this had a correlation with clinical improvement. Serial plasma TB4 levels were obtained from patients and concentrations were measured in those who received stem cells and those who did not. The study was conducted by Dr. F.A. Choudry and his colleagues in the Department of Cardiology, London Chest Hospital, Barts Health Trust; the British Heart Foundation Laboratories, Department of Medicine, University College and Centre for Clinical Pharmacology, Cardiovascular Biomedical Research Unit; and The William Harvey Research Institute, Queen Mary University, all located in London, UK.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RGRX:US $0.43 USD +0.0066

RGRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RGRX.
View Industry Companies
 

Industry Analysis

RGRX

Industry Average

Valuation RGRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 970.0x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 944.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REGENERX BIOPHARMACEUTICALS, please visit www.regenerx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.